Skip to main content
Signal8

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

$BCLIPress releaseNov 16, 2026, 4:01 PM ETRead the release

BrainStorm Cell Therapeutics reported a Q3 2026 net loss of $1.7 million ($0.14 per share), narrowed from $2.1 million a year earlier. The critical figure is liquidity: total cash including restricted cash was only ~$0.35 million at quarter end, far below the quarterly burn rate, and the balance sheet shows a $12.3 million stockholders' deficit and rising payables and employee-related liabilities. Operationally, the company is preparing to launch the Phase 3b ENDURANCE trial of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, and installed former FDA official Peter J. Pitts as Executive Chairman.

Key figures

Revenue Yoy
0
Net loss q3
1733000
Ga expense q3
1092000
Rd expense q3
523000
Restricted cash
185000
Shares outstanding
14259377
Cash and equivalents
163000
Net loss prior year q3
2106000
Shares outstanding dec 2025
11034775

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.